PSI-7851, a pronucleotide of β-D-2′-deoxy-2′-fluoro- 2′-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 8, 2010, Pages 3187-3196

  Lam, Angela M ^a   Murakami, Eisuke ^a   Espiritu, Christine ^a   Micolochick Steuer, Holly M ^a   Niu, Congrong ^a   Keilman, Meg ^a   Bao, Haiying ^a   Zennou, Veronique ^a   Bourne, Nigel ^b   Julander, Justin G ^c   Morrey, John D ^c   Smee, Donald F ^c   Frick, David N ^d   Heck, Julie A ^d   Wang, Peiyuan ^a   Nagarathnam, Dhanapalan ^a   Ross, Bruce S ^a   Sofia, Michael J ^a   Otto, Michael J ^a   Furman, Phillip A ^a  

^a PHARMASSET INC   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c UTAH STATE UNIVERSITY   (United States)

^d NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA DEXTRO 2' DEOXY 2' FLUORO 2' C METHYLURIDINE MONOPHOSPHATE; NONSTRUCTURAL PROTEIN 5B; NUCLEOSIDE ANALOG; PSI 6206; PSI 7409; PSI 7411; PSI 7851; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CROSS RESISTANCE; DRUG CYTOTOXICITY; DRUG STRUCTURE; GENOTYPE; HEPATITIS C VIRUS; NONHUMAN; PRIORITY JOURNAL; REBOUND; REPLICON; VIRUS INHIBITION; VIRUS REPLICATION;

AMIDES; ANTIVIRAL AGENTS; CELL LINE, TUMOR; DEOXYURACIL NUCLEOTIDES; ENZYME INHIBITORS; GENOTYPE; HEPACIVIRUS; HUMANS; PHOSPHORIC ACIDS; PRODRUGS; REPLICON; RNA REPLICASE; RNA, VIRAL; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 77954646871     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00399-10     Document Type: Article

References (61)

1. Ali, S., V. Leveque, S. Le Pogam, H. Ma, F. Philipp, N. Inocencio, M. Smith, A. Alker, H. Kang, I. Najera, K. Klumpp, J. Symons, N. Cammack, and W. R. Jiang. 2008. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479. Antimicrob. Agents Chemother. 52:4356-4369.
2. Alter, H. J. 2005. HCV natural history: the retrospective and prospective in perspective. J. Hepatol. 43:550-552.
3. Bourne, N., R. B. Pyles, M. Yi, R. L. Veselenak, M. M. Davis, and S. M. Lemon. 2005. Screening for hepatitis C virus antiviral activity with a cell-based secreted alkaline phosphatase reporter replicon system. Antiviral Res. 67:76-82. (Pubitemid 41112623)
4. Charneau, P., M. Alizon, and F. Clavel. 1992. A second origin of DNA plus-strand synthesis is required for optimal human immunodeficiency virus replication. J. Virol. 66:2814-2820.
5. Clark, J. L., J. C. Mason, L. Hollecker, L. J. Stuyver, P. M. Tharnish, T. R. McBrayer, M. J. Otto, P. A. Furman, R. F. Schinazi, and K. A. Watanabe. 2006. Synthesis and antiviral activity of 2′-deoxy-2′-fluoro- 2′-C-methyl purine nucleosides as inhibitors of hepatitis C virus RNA replication. Bioorg. Med. Chem. Lett. 16:1712-1715.
6. Fleischer, R. D., and A. S. Lok. 2009. Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. J. Hepatol. 51:787-791.
7. Foster, G., and P. Mathurin. 2008. Hepatitis C virus therapy to date. Antivir. Ther. 13(Suppl. 1):3-8.
8. Fried, M. W., M. L. Shiffman, K. R. Reddy, C. Smith, G. Marinos, F. L. Goncales, Jr., D. Haussinger, M. Diago, G. Carosi, D. Dhumeaux, A. Craxi, A. Lin, J. Hoffman, and J. Yu. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:975-982.
9. Fry, M., and L. A. Loeb. 1986. Animal cell DNA polymerases. CRC Press Inc., Boca Raton, FL.
10. Gane, E., S. K. Roberts, C. A. Stedman, P. W. Angus, B. Ritchie, R. Elston, D. Ipe, P. N. Morcos, I. Najera, T. Chu, M. M. Berry, W. Z. Bradford, M. Laughlin, N. Shulman, and P. F. Smith. 2009. Combination therapy with a nucleoside polymerase (R7128) and protease (R7227/ITMN-191) inhibitor in HCV: safety, pharmacokinetics, and virologic results from INFORM-1, abstr. 193. Abstr. 60th Annu. Meet. Am. Assoc. Study Liver Dis. American Association for the Study of Liver Diseases, Alexandria, VA.
11. Hadziyannis, S. J., H. Sette, Jr., T. R. Morgan, V. Balan, M. Diago, P. Marcellin, G. Ramadori, H. Bodenheimer, Jr., D. Bernstein, M. Rizzetto, S. Zeuzem, P. J. Pockros, A. Lin, A. M. Ackrill, et al. 2004. Peginterferon- α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140:346-355.
12. Hassan, A. E., B. S. Pai, S. Lostia, L. Stuyver, M. J. Otto, R. F. Schinazi, and K. A. Watanabe. 2003. Synthesis and antiviral evaluation of 2′,3′-dideoxy2′-fluoro-3′- C-hydroxymethyl-beta-D- arabinofuranosyl pyrimidine nucleosides. Nucleosides Nucleotides Nucleic Acids 22:891-894.
13. Heck, J. A., A. M. Lam, N. Narayanan, and D. N. Frick. 2008. Effects of mutagenic and chain-terminating nucleotide analogs on enzymes isolated from hepatitis C virus strains of various genotypes. Antimicrob. Agents Chemother. 52:1901-1911.
14. Hecker, S. J., and M. D. Erion. 2008. Prodrugs of phosphates and phosphonates. J. Med. Chem. 51:2328-2345.
15. Herlihy, K. J., J. P. Graham, R. Kumpf, A. K. Patick, R. Duggal, and S. T. Shi. 2008. Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors. Antimicrob. Agents Chemother. 52:3523-3531.
16. Ishii, K., Y. Tanaka, C. C. Yap, H. Aizaki, Y. Matsuura, and T. Miyamura. 1999. Expression of hepatitis C virus NS5B protein: characterization of its RNA polymerase activity and RNA binding. Hepatology 29:1227-1235.
17. Kato, T., T. Date, M. Miyamoto, A. Furusaka, K. Tokushige, M. Mizokami, and T. Wakita. 2003. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 125:1808-1817. (Pubitemid 37500445)
18. Kim, A. Y., and J. Timm. 2008. Resistance mechanisms in HCV: from evolution to intervention. Expert Rev. Anti Infect. Ther. 6:463-478.
19. Kolykhalov, A. A., K. Mihalik, S. M. Feinstone, and C. M. Rice. 2000. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′ nontranslated region are essential for virus replication in vivo. J. Virol. 74:2046-2051.
20. Kukhanova, M., S. H. Liu, D. Mozzherin, T. S. Lin, C. K. Chu, and Y. C. Cheng. 1995. L- and D-enantiomers of 2′,3′-dideoxycytidine 5′-triphosphate analogs as substrates for human DNA polymerases. Implications for the mechanism of toxicity. J. Biol. Chem. 270:23055-23059.
21. Kwong, A. D., L. McNair, I. Jacobson, and S. George. 2008. Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors. Curr. Opin. Pharmacol. 8:522-531.
22. Ladner, S. K., M. J. Otto, C. S. Barker, K. Zaifert, G. H. Wang, J. T. Guo, C. Seeger, and R. W. King. 1997. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob. Agents Chemother. 41:1715-1720.
23. Lalezari, J., E. Gane, M. Rodriguez-Torres, E. DeJesus, D. Nelson, G. Everson, I. Jacobson, R. Reddy, G. Z. Hill, A. Beard, W. T. Symonds, M. M. Berry, and J. G. McHutchison. 2008. Potent antiviral activity of the HCV nucleoside polymerase inhibitor R7128 with PEG-IFN and ribavirin: interim results of R7128 500mg BID for 28 days, abstr. 66. Abstr. 43rd Annu. Meet. Eur. Assoc. Study Liver, Milan, Italy, 23 to 27 April 2008. EASL, Geneva, Switzerland.
24. Lam, A. M., and D. N. Frick. 2006. Hepatitis C virus subgenomic replicon requires an active NS3 RNA helicase. J. Virol. 80:404-411.
25. Lawitz, E., M. Rodriguez-Torres, J. Denning, E. Albanis, W. T. Symonds, and M. M. Berry. 2009. Potent antiviral activity observed with PSI-7851, a novel nucleotide polymerase inhibitor for HCV, following multiple ascending oral doses for 3 days in patients with chronic HCV infection, abstr. 102. HEP DART 2009, Kohala Coast, HI, 6 to 10 December 2009.
26. Le Guillou-Guillemette, H., S. Vallet, C. Gaudy-Graffin, C. Payan, A. Pivert, A. Goudeau, and F. Lunel-Fabiani. 2007. Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy. World J. Gastroenterol. 13:2416-2426.
27. Lemm, J. A., D. O'Boyle II, M. Liu, P. T. Nower, R. Colonno, M. S. Deshpande, L. B. Snyder, S. W. Martin, D. R. St. Laurent, M. H. Serrano-Wu, J. L. Romine, N. A. Meanwell, and M. Gao. 2010. Identification of hepatitis C virus NS5A inhibitors. J. Virol. 84:482-491.
28. Le Pogam, S., A. Seshaadri, A. Kosaka, S. Hu, A. Beard, J. Symons, N. Cammack, and I. Najera. 2008. Low level of resistance and low viral fitness in vitro and absence of resistance mutations in baseline quasispecies may contribute to high barrier to R1626 resistance in vivo, abstr. 6. Progr. 3rd Int. Workshop Hepatitis C: Resist. New Comp. Virology Education, Utrecht, Netherlands.
29. Le Pogam, S., W. R. Jiang, V. Leveque, S. Rajyaguru, H. Ma, H. Kang, S. Jiang, M. Singer, S. Ali, K. Klumpp, D. Smith, J. Symons, N. Cammack, and I. Najera. 2006. In vitro selected Con1 subgenomic replicons resistant to 2′-C-methyl-cytidine or to R1479 show lack of cross resistance. Virology 351:349-359.
30. Lewis, W., B. J. Day, and W. C. Copeland. 2003. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat. Rev. Drug Discov. 2:812-822.
31. Lohmann, V., S. Hoffmann, U. Herian, F. Penin, and R. Bartenschlager. 2003. Viral and cellular determinants of hepatitis C virus RNA replication in cell culture. J. Virol. 77:3007-3019. (Pubitemid 36228086)
32. Lohmann, V., F. Korner, U. Herian, and R. Bartenschlager. 1997. Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity. J. Virol. 71:8416-8428. (Pubitemid 27446422)
33. Ludmerer, S. W., D. J. Graham, E. Boots, E. M. Murray, A. Simcoe, E. J. Markel, J. A. Grobler, O. A. Flores, D. B. Olsen, D. J. Hazuda, and R. L. LaFemina. 2005. Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay. Antimicrob. Agents Chemother. 49:2059-2069.
34. Ma, H., W. R. Jiang, N. Robledo, V. Leveque, S. Ali, T. Lara-Jaime, M. Masjedizadeh, D. B. Smith, N. Cammack, K. Klumpp, and J. Symons. 2007. Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-D-2′-deoxy-2′-fluoro-2′-C-methylcytidine (PSI-6130) and identification of a novel active 5′-triphosphate species. J. Biol. Chem. 282: 29812-29820.
35. Manns, M. P., J. G. McHutchison, S. C. Gordon, V. K. Rustgi, M. Shiffman, R. Reindollar, Z. D. Goodman, K. Koury, M. Ling, and J. K. Albrecht. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965.
36. McCown, M. F., S. Rajyaguru, S. Le Pogam, S. Ali, W. R. Jiang, H. Kang, J. Symons, N. Cammack, and I. Najera. 2008. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob. Agents Chemother. 52:1604-1612.
37. McManus, N. H. 1976. Microtiter assay for interferon: microspectrophotometric quantitation of cytopathic effect. Appl. Environ. Microbiol. 31:35-38.
38. Migliaccio, G., J. E. Tomassini, S. S. Carroll, L. Tomei, S. Altamura, B. Bhat, L. Bartholomew, M. R. Bosserman, A. Ceccacci, L. F. Colwell, R. Cortese, R. De Francesco, A. B. Eldrup, K. L. Getty, X. S. Hou, R. L. LaFemina, S. W. Ludmerer, M. MacCoss, D. R. McMasters, M. W. Stahlhut, D. B. Olsen, D. J. Hazuda, and O. A. Flores. 2003. Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J. Biol. Chem. 278:49164-49170.
39. Moyle, G. 2000. Toxicity of antiretroviral nucleoside and nucleotide analogues: is mitochondrial toxicity the only mechanism? Drug Saf. 23:467-481.
40. Murakami, E., H. Bao, A. Basavapathruni, C. M. Bailey, J. Du, H. M. Steuer, C. Niu, T. Whitaker, K. S. Anderson, M. J. Otto, and P. A. Furman. 2007. Mechanism of action of (-)-(2R,4R)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl) thymine as an anti-HIV agent. Antivir. Chem. Chemother. 18:83-92.
41. Murakami, E., H. Bao, M. Ramesh, T. R. McBrayer, T. Whitaker, H. M. Micolochick Steuer, R. F. Schinazi, L. J. Stuyver, A. Obikhod, M. J. Otto, and P. A. Furman. 2007. Mechanism of activation of beta-D-2′-deoxy-2′- fluoro-2′-C-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase. Antimicrob. Agents Chemother. 51:503-509.
42. Murakami, E., C. Niu, H. Bao, H. M. Micolochick Steuer, T. Whitaker, T. Nachman, M. A. Sofia, P. Wang, M. J. Otto, and P. A. Furman. 2008. The mechanism of action of beta-D-2′-deoxy-2′-fluoro-2′-C-methylcytidine involves a second metabolic pathway leading to beta-D-2′-deoxy-2′- fluoro-2′- C-methyluridine 5′-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob. Agents Chemother. 52:458-464.
43. Olsen, D. B., A. B. Eldrup, L. Bartholomew, B. Bhat, M. R. Bosserman, A. Ceccacci, L. F. Colwell, J. F. Fay, O. A. Flores, K. L. Getty, J. A. Grobler, R. L. LaFemina, E. J. Markel, G. Migliaccio, M. Prhavc, M. W. Stahlhut, J. E. Tomassini, M. MacCoss, D. J. Hazuda, and S. S. Carroll. 2004. A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties. Antimicrob. Agents Chemother. 48:3944-3953.
44. Reddy, R., M. Rodriguez-Torres, E. Gane, R. Robson, J. Lalezari, G. Everson, E. DeJesus, J. G. McHutchison, H. Vargas, A. Beard, C. A. Rodriguez, G. Hill, W. T. Symonds, and M. M. Berry. 2007. Antiviral activity, pharmacokinetics, safety, and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy, abstr. LB9. Abstr. 58th Annu. Meet. Am. Assoc. Study Liver Dis. American Association for the Study of Liver Diseases, Alexandria, VA.
45. Rodriguez-Torres, M., E. Lawitz, S. Flach, J. M. Denning, E. Albanis, W. T. Symonds, and M. M. Berry. 2009. Antiviral activity, pharmacokinetics, safety, and tolerability of PSI-7851, a novel nucleotide polymerase inhibitor for HCV, following single and 3 day multiple ascending oral doses in healthy volunteers and patients with chronic HCV infection, abstr. LB17. Abstr. 60th Annu. Meet. Am. Assoc. Study Liver Dis. American Association for the Study of Liver Diseases, Alexandria, VA.
46. Schmitz, U., and S. L. Tan. 2008. NS5A: from obscurity to new target for HCV therapy. Recent Pat. Antiinfect. Drug Discov. 3:77-92.
47. Sofia, M. A., P. Wang, J. Du, H. M. Micolochick Steuer, C. Niu, P. A. Furman, and M. J. Otto. 2007. Beta-D-2′-deoxy-2′-fluoro-2′-C- methyluridine phosphoramidates: potent and selective inhibitors of HCV RNA replication, abstr. P-259. Progr. 14th Int. Symp. Hepatitis C Virus Related Viruses, Glasgow, Scotland, 9 to 13 September 2007. European Association for the Study of the Liver, Geneva, Switzerland.
48. Sofia, M. A., P. Wang, J. Du, H. M. Micolochick Steuer, C. Niu, B. Ross, S. Rachakonda, D. Bao, W. T. Symonds, P. A. Furman, M. J. Otto, and D. Nagaratham. 2008. Beta-D-2′-deoxy-2′-fluoro-2′-C-methyluridine (PSI-6206) phosphoramidates: potent liver targeting nucleoside inhibitors of HCV RNA replication, abstr. MEDI-330. Progr. 238th ACS Natl. Meet. American Chemical Society,Washington, DC.
49. Sommadossi, J. P., and R. Carlisle. 1987. Toxicity of 3′-azido-3′-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl) guanine for normal human hematopoietic progenitor cells in vitro. Antimicrob. Agents Chemother. 31:452-454.
50. Sommadossi, J. P., R. F. Schinazi, C. K. Chu, and M. Y. Xie. 1992. Comparison of cytotoxicity of the (-)- and (+)-enantiomer of 2′,3′-dideoxy-3′- thiacytidine in normal human bone marrow progenitor cells. Biochem. Pharmacol. 44:1921-1925.
51. Stuyver, L. J., S. Lostia, M. Adams, J. S. Mathew, B. S. Pai, J. Grier, P. M. Tharnish, Y. Choi, Y. Chong, H. Choo, C. K. Chu, M. J. Otto, and R. F. Schinazi. 2002. Antiviral activities and cellular toxicities of modified 2′,3′-dideoxy-2′,3′-didehydrocytidine analogues. Antimicrob. Agents Chemother. 46:3854-3860.
52. Stuyver, L. J., T. R. McBrayer, P. M. Tharnish, J. Clark, L. Hollecker, S. Lostia, T. Nachman, J. Grier, M. A. Bennett, M. Y. Xie, R. F. Schinazi, J. D. Morrey, J. L. Julander, P. A. Furman, and M. J. Otto. 2006. Inhibition of hepatitis C replicon RNA synthesis by beta-D-2′-deoxy-2′-fluoro- 2′-C-methylcytidine: a specific inhibitor of hepatitis C virus replication. Antivir. Chem. Chemother. 17:79-87.
53. Stuyver, L. J., T. R. McBrayer, P. M. Tharnish, A. E. Hassan, C. K. Chu, K. W. Pankiewicz, K. A. Watanabe, R. F. Schinazi, and M. J. Otto. 2003. Dynamics of subgenomic hepatitis C virus replicon RNA levels in Huh-7 cells after exposure to nucleoside antimetabolites. J. Virol. 77:10689-10694.
54. Tanji, N., K. Tanji, N. Kambham, G. S. Markowitz, A. Bell, and V. D. D'Agati, V. 2001. Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Hum. Pathol. 32:734-740.
55. Tomei, L., S. Altamura, L. Bartholomew, M. Bisbocci, C. Bailey, M. Bosserman, A. Cellucci, E. Forte, I. Incitti, L. Orsatti, U. Koch, R. De Francesco, D. B. Olsen, S. S. Carroll, and G. Migliaccio. 2004. Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides. J. Virol. 78:938-946.
56. Wakita, T., T. Pietschmann, T. Kato, T. Date, M. Miyamoto, Z. Zhao, K. Murthy, A. Habermann, H. G. Krausslich, M. Mizokami, R. Bartenschlager, and T. J. Liang. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11:791-796.
57. Yamada, K., and R. Itoh. 1994. Involvement of DNA polymerase delta and/or epsilon in joining UV-induced DNA single strand breaks in human fibroblasts (comparison of effects of butylphenyldeoxyguanosine with aphidicolin). Biochim. Biophys. Acta 1219:302-306. (Pubitemid 24319687)
58. Yamashita, T., S. Kaneko, Y. Shirota, W. Qin, T. Nomura, K. Kobayashi, and S. Murakami. 1998. RNA-dependent RNA polymerase activity of the soluble recombinant hepatitis C virus NS5B protein truncated at the Cterminal region. J. Biol. Chem. 273:15479-15486.
59. Yi, M., F. Bodola, and S. M. Lemon. 2002. Subgenomic hepatitis C virus replicons inducing expression of a secreted enzymatic reporter protein. Virology 304:197-210.
60. Yi, M., and S. M. Lemon. 2004. Adaptive mutations producing efficient replication of genotype 1a hepatitis C virus RNA in normal Huh7 cells. J. Virol. 78:7904-7915.
61. Yi, M., R. A. Villanueva, D. L. Thomas, T. Wakita, and S. M. Lemon. 2006. Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc. Natl. Acad. Sci. U. S. A. 103:2310-2315.